Interventional Bioremediation of Microbiota in Metabolic Syndrome

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE2

Total Enrollment

12 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-06-30

Study Completion Date

2018-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine whether changing the microbial composition in the colon can improve metabolism of sugar in people who are on the verge of developing diabetes (pre-diabetics). Study participants will undergo a fecal microbiota transplantation (FMT) using material from lean donors, as well as a series of tests prior to and after the transplant. The investigators will examine any changes in fecal bacterial composition associated with FMT and determine if any observed changes have an influence on blood sugar metabolism.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Prevention of Persistence of Bacterial Vaginosis

NCT00741845

Bacterial Vaginosis

TERMINATED PHASE3

The Effect of Clindamycin and a Live Biotherapeutic on the Reproductive Outcomes of IVF Patients With Abnormal Vaginal Microbiota

NCT05166746

Bacterial Vaginoses Infertility, Female

UNKNOWN PHASE2

Study by Metagenomics and Culturomicsapproaches of Bacterial and Viral Flora of Diabetic Foot Infection

NCT02565940

Diabetic Foot Infection

UNKNOWN

A Phase 1/2 Study to Evaluate the Safety, PK and Efficacy of TNP-2092 Administered Via IA Injection in PJI Participants

NCT06889701

Periprosthetic Joint Infection (PJI)

RECRUITING PHASE1/PHASE2

Application of Daptomycin in MRSA Infected Diabetic Foot in Comparison to Vancomycin Treatment

NCT01199783

Diabetic Foot

TERMINATED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pre-Diabetes

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Antibiotics prior to FMT

One week prior to FMT, a course of three oral antibiotics are taken: Vancomycin 500mg, Neomycin 1000mg, and Clindamycin 300mg.

Group Type EXPERIMENTAL

Vancomycin

Intervention Type DRUG

Vancomycin 3 times a day for 7 days

Neomycin

Intervention Type DRUG

Neomycin 3 times a day for 1 day

Clindamycin

Intervention Type DRUG

Clindamycin 3 times a day for 5 days

Fecal Microbiota Transplantation

Intervention Type PROCEDURE

FMT conducted via colonoscopy

Placebo prior to FMT

One week prior to FMT, a course of three sugar pills identical to each antibiotic.

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type OTHER

Placebo pills identical in appearance to each antibiotics to be taken on the same schedule as each antibiotic

Fecal Microbiota Transplantation

Intervention Type PROCEDURE

FMT conducted via colonoscopy

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Vancomycin

Vancomycin 3 times a day for 7 days

Intervention Type DRUG

Placebo

Placebo pills identical in appearance to each antibiotics to be taken on the same schedule as each antibiotic

Intervention Type OTHER

Neomycin

Neomycin 3 times a day for 1 day

Intervention Type DRUG

Clindamycin

Clindamycin 3 times a day for 5 days

Intervention Type DRUG

Fecal Microbiota Transplantation

FMT conducted via colonoscopy

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Provide informed consent
2. Ambulatory and community dwelling
3. Age 18 - 70 years of age
4. Able and willing to comply with the study schedule and procedures
5. Pre-diabetic with fasting blood glucose \> 100 mg/dL and/or blood glucose 140-200 mg/dL 2-hours after ingestion of 75 gm glucose and/or Hemoglobin A1c \> 5.7-6.5 percent

Exclusion Criteria

1. Serious, concomitant illness that, in the opinion of the Investigator, would interfere with evaluation of safety or efficacy, or put the subject at risk of harm from study participation.
2. Known inflammatory bowel disease (Crohn's disease, ulcerative colitis, lymphocytic colitis).
3. Current abnormal liver tests that may be attributed to a cause other than non-alcoholic liver disease. Note: These exclusionary conditions may include viral hepatitis, alcoholic liver disease, hemochromatosis, Wilson's disease, medication-induced liver test abnormalities, celiac disease.
4. Renal insufficiency, defined as creatinine ≤ 1.25 mg/dL
5. Significant alcohol use, defined as \> 20 g/day in females and \> 30 g/day in males for a period of 3 months within one year prior to screening.
6. Underlying chronic gastrointestinal disease that can cause diarrhea, including short bowel syndrome, diarrhea-predominant irritable bowel syndrome, malabsorption, celiac disease.
7. History of partial or complete colectomy.
8. History of malabsorptive bariatric surgery.
9. Use of insulin or hypoglycemic medications.
10. History of anaphylactic food allergies, e.g., peanuts, seafood.
11. Food intolerances and allergies, including gluten sensitivity, lactose intolerance, and intolerance of high fiber dietary content.
12. Symptomatic problems associated with intestinal gas and bloating.
13. Irritable bowel syndrome, including diarrhea-dominant, constipation-dominant, and mixed.
14. Functional GI disorder.
15. Unable to tolerate a colonoscopy.
16. Presence of an indwelling intravenous line.
17. Infection requiring antibiotics other than the conditioning antibiotics during the study period.
18. Inability to take vancomycin, neomycin, and clindamycin antibiotics prior to FMT due to known hypersensitivity or intolerance.
19. Major genetic immune dysfunction (e.g., common variable immune deficiency).
20. Acquired immune deficiencies due to infections such as HIV.
21. Immunosuppressive medications including one of the following: systemic corticosteroids, calcineurin inhibitors, thiopurines, methotrexate, biologics (e.g., anti-tumor necrosis factor drugs), cancer chemotherapy.
22. Planned use of oral probiotics while on study.
23. Planned or ongoing chemotherapy for malignancy.
24. Planned antibiotic therapy within the period of the study, e.g., perioperative antibiotics.
25. Pregnant or lactating. Female participants of child-bearing age and their partners will be counseled on contraceptive measures to prevent pregnancy during the study period.
26. History of drug or alcohol abuse in the past 2 years.
27. Currently participating in another clinical study.
28. Legally incompetent and unable to understand the study's purpose, significance and consequences, and to make decisions accordingly.
29. Presence of metal implants, such as surgical clips or pacemakers, which will preclude performance of MRI tests.
30. Inability to undergo MRI testing for any reason, e.g., claustrophobia.

Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No